2. Academic Validation
  3. Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

  • J Clin Oncol. 2023 Feb 20;41(6):1323. doi: 10.1200/JCO.22.01759.
Zachary R McCaw 1,  Ethan B Ludmir 1,  Lee-Jen Wei 1
Affiliations

Affiliation

  • 1 Zachary R. McCaw, PhD, Insitro, South San Francisco, CA; Ethan B. Ludmir, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Lee-Jen Wei, PhD, Harvard T.H. Chan School of Public Health, Boston, MA.
PMID: 36331242 DOI: 10.1200/JCO.22.01759
Figures
Products